Scott Rocklage 5AM’s managing partner, a role he got in 2004. He had joined the company as a Venture Partner in 2003. His scientific background, as well as the thirty years’ experience he acquired while working in healthcare management has reinforced his background. Through his leadership responsibilities, he helped with the approval of three new drug applications, namely Teslascan, Cubicin, and Omniscan.
Scott was the CEO and Chairman of Cubist Pharmaceuticals and the CEO and President of Nycomed Salutar before joining 5AM. Mr. Rocklage also worked as the President and CEO of Amersham Health. Other positions Scott has held include being Cidara Therapeutics Chairman of the board and Novra Therapeutics Chairman. His background and vast experience in science, healthcare, and strategic leadership roles have helped him become an effective strategist and leader in the venture capital, healthcare, and pharmaceutical world.
Scott Rocklage earned a Bachelor of Science degree in Chemistry at the California University of Berkley as well as a Ph.D. (Doctor of Philosophy) degree in Chemistry from the MIT (Massachusetts Institute of Technology). He won a Nobel Prize in 2005 after conducting research in Richard R. Schrock’s laboratory while at MIT.
Growing 5AM Ventures
Through his leadership, 5AM has become a leader in the industry. The company supports entities that develop solutions for solving healthcare needs using cutting-edge science and medicine breakthroughs. All firms that are subject to 5AM ventures support are leading in developing untraditional approaches for diagnosing, preventing, and treating a broad range of medical conditions.
One strategy that has helped Scott to grow 5AM is staying true to what the business stands for and not drifting too far from their strengths. He is well organized when it comes to calendaring management and prioritization, which are some of the practices that help Scott to remain productive as an entrepreneur.